Micalis Institute, INRAE, AgroParisTech, Université Paris-Saclay, Jouy en Josas, France
Micalis Institute, INRAE, AgroParisTech, Université Paris-Saclay, Jouy en Josas, France.
mBio. 2021 Feb 2;12(1):e03193-20. doi: 10.1128/mBio.03193-20.
Fatty acid biosynthesis (FASII) enzymes are considered valid targets for antimicrobial drug development against the human pathogen However, incorporation of host fatty acids confers FASII antibiotic adaptation that compromises prospective treatments. adapts to FASII inhibitors by first entering a nonreplicative latency period, followed by outgrowth. Here, we used transcriptional fusions and direct metabolite measurements to investigate the factors that dictate the duration of latency prior to outgrowth. We show that stringent response induction leads to repression of FASII and phospholipid synthesis genes. (p)ppGpp induction inhibits synthesis of malonyl-CoA, a molecule that derepresses FapR, a key regulator of FASII and phospholipid synthesis. Anti-FASII treatment also triggers transient expression of (p)ppGpp-regulated genes during the anti-FASII latency phase, with concomitant repression of FapR regulon expression. These effects are reversed upon outgrowth. GTP depletion, a known consequence of the stringent response, also occurs during FASII latency, and is proposed as the common signal linking these responses. We next showed that anti-FASII treatment shifts malonyl-CoA distribution between its interactants FapR and FabD, toward FapR, increasing expression of the phospholipid synthesis genes and during outgrowth. We conclude that components of the stringent response dictate malonyl-CoA availability in FASII regulation, and contribute to latency prior to anti-FASII-adapted outgrowth. A combinatory approach, coupling a (p)ppGpp inducer and an anti-FASII, blocks outgrowth, opening perspectives for bi-therapy treatment. is a major human bacterial pathogen for which new inhibitors are urgently needed. Antibiotic development has centered on the fatty acid synthesis (FASII) pathway, which provides the building blocks for bacterial membrane phospholipids. However, overcomes FASII inhibition and adapts to anti-FASII by using exogenous fatty acids that are abundant in host environments. This adaptation mechanism comprises a transient latency period followed by bacterial outgrowth. Here, we use metabolite sensors and promoter reporters to show that responses to stringent conditions and to FASII inhibition intersect, in that both involve GTP and malonyl-CoA. These two signaling molecules contribute to modulating the duration of latency prior to adaptation outgrowth. We exploit these novel findings to propose a bi-therapy treatment against staphylococcal infections.
脂肪酸生物合成(FASII)酶被认为是针对人类病原体的抗菌药物开发的有效靶点。然而,宿主脂肪酸的掺入赋予了 FASII 抗生素适应性,从而损害了预期的治疗效果。适应 FASII 抑制剂的方法是首先进入非复制潜伏期,然后再进行生长。在这里,我们使用转录融合和直接代谢物测量来研究决定生长前潜伏期长短的因素。我们表明,严格响应诱导导致 FASII 和磷脂合成基因的抑制。(p)ppGpp 的诱导抑制了丙二酰辅酶 A 的合成,丙二酰辅酶 A 是一种解除 FapR 抑制的分子,FapR 是 FASII 和磷脂合成的关键调节剂。抗 FASII 治疗也会在抗 FASII 潜伏期期间触发 (p)ppGpp 调节基因的短暂表达,同时抑制 FapR 调节子的表达。这些作用在生长后逆转。GTP 耗尽是严格响应的已知后果,也发生在 FASII 潜伏期期间,被提议作为连接这些反应的共同信号。我们接下来表明,抗 FASII 治疗将丙二酰辅酶 A 在其相互作用物 FapR 和 FabD 之间的分布转移到 FapR 上,从而在生长过程中增加了磷脂合成基因 和 的表达。我们得出的结论是,严格响应的成分决定了 FASII 调节中的丙二酰辅酶 A 的可用性,并有助于抗 FASII 适应生长前的潜伏期。联合使用 (p)ppGpp 诱导剂和抗 FASII 的方法可以阻断 的生长,为双治疗开辟了前景。是一种主要的人类细菌病原体,迫切需要新的抑制剂。抗生素的开发集中在脂肪酸合成(FASII)途径上,该途径为细菌膜磷脂提供了构建块。然而,通过利用宿主环境中丰富的外源脂肪酸,克服了 FASII 抑制并适应了抗 FASII。这种适应机制包括一个短暂的潜伏期,随后是细菌生长。在这里,我们使用代谢物传感器和启动子报告基因来表明,严格条件和 FASII 抑制的反应相交,因为两者都涉及 GTP 和丙二酰辅酶 A。这两个信号分子有助于调节适应生长前的潜伏期持续时间。我们利用这些新发现来提出一种针对葡萄球菌感染的双治疗方法。